Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
Open Access
- 10 April 2023
- journal article
- letter
- Published by Springer Nature in Blood Cancer Journal
- Vol. 13 (1) , 1-4
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Comparison between GATA2 and DDX41-mutated myeloid neoplasmsLeukemia Research, 2022
- Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemiaBone Marrow Transplantation, 2022
- The genetic landscape of germlineDDX41variants predisposing to myeloid neoplasmsBlood, 2022
- Prognostic impact ofDDX41germline mutations in intensively treated acute myeloid leukemia patients: an ALFA-FILO studyBlood, 2022
- Genetic features and clinical outcomes of patients with isolated and comutatedDDX41-mutated myeloid neoplasmsBlood Advances, 2022
- Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasiaCell Stem Cell, 2021
- Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromesAmerican Journal of Hematology, 2021
- Germline DDX41 mutations define a significant entity within adult MDS/AML patientsBlood, 2019
- Inherited and Somatic Defects in DDX41 in Myeloid NeoplasmsCancer Cell, 2015